Analysts expect Lyell Immunopharma, Inc. to report revenue of 4,430.70 for Q3 26, against a range of 4,175.02 to 4,686.38. The most recent reported quarter, Q2 26, came in at 4,000.00, a 6.6% beat against the 3,753.57 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 34,000.00 | 11,000.00 | 7,000.00 | 8,000.00 | 15,000.00 | 6,000.00 | 2,000.00 | 4,000.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 3,962.73 | 0.00 | 15,815.82 | 5,032.88 | 3,998.21 | 4,686.38 | 3,707.51 | 7,497.84 | 7,449.95 | 6,744.53 | 3,180.67 | 17,126.87 | 29,282.70 | ||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 3,674.43 | 0.00 | 13,067.22 | 4,139.40 | 3,508.93 | 4,175.02 | 3,339.81 | 6,586.40 | 6,871.35 | 5,757.97 | 2,761.33 | 15,321.85 | 25,224.28 | ||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 3,818.58 | 0.00 | 14,441.52 | 4,586.14 | 3,753.57 | 4,430.70 | 3,523.66 | 7,042.12 | 7,160.65 | 6,251.25 | 2,971.00 | 16,224.36 | 27,253.49 |
Analysts expect Lyell Immunopharma, Inc. to report earnings per share of -2.16 for Q3 26, against a range of -2.34 to -1.98. The most recent reported quarter, Q2 26, came in at -1.92, a 2.5% beat against the -1.97 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -3.40 | -8.90 | -1.86 | -2.89 | -2.13 | -6.85 | -1.10 | -1.92 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -3.62 | -3.20 | -3.57 | -3.42 | -2.61 | -2.19 | -1.88 | -1.88 | -1.98 | -2.05 | -1.97 | -2.11 | -1.80 | -2.45 | -0.58 | -1.42 | ||||||||||
| Low Estimate | -4.38 | -3.76 | -4.01 | -3.94 | -2.97 | -2.39 | -2.10 | -2.06 | -2.34 | -2.39 | -2.13 | -2.45 | -2.06 | -2.81 | -0.64 | -1.70 | ||||||||||
| Consensus Estimate | -4.00 | -3.48 | -3.79 | -3.68 | -2.79 | -2.29 | -1.99 | -1.97 | -2.16 | -2.22 | -2.05 | -2.28 | -1.93 | -2.63 | -0.61 | -1.56 |
Pull Wall Street consensus for Lyell Immunopharma, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=LYEL&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "LYEL", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=LYEL&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();